Zealand Announces Advance by Sanofi of LixiLan, the Single Injection Lyxumia(R)/Lantus(R) Combination Product, Towards Phase III Development and a Related Milestone Payment

Zealand Pharma A/S (NASDAQ OMX Copenhagen:ZEAL) ("Zealand") announces that under its license agreement with Sanofi

covering Lyxumia(r) (lixisenatide) and any combination product including lixisenatide, a milestone has been achieved in the advance of LixiLan, the once-daily single injection Lantus(r) (basal insulin) / Lyxumia(r) (lixisenatide) combination product, towards start of Phase III development in the 1st quarter of 2014. The milestone relates to the approval of the first Phase III study protocol for LixiLan by a Health Authority, triggering a USD 15 million payment to Zealand.